These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35987855)

  • 1. [Prevention and management of pegaspargase associated-toxicities (excluding coagulation abnormalities). Recommendations of the French Society of Children and Adolescent Cancers (Leukemia committee)].
    Poirée M; Neumann F; Thomas C; Simon P; Lunven AFR; Plantaz D; Doulet ST; Strullu M
    Bull Cancer; 2022 Nov; 109(11):1125-1131. PubMed ID: 35987855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
    Heo YA; Syed YY; Keam SJ
    Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peg-asparaginase for acute lymphoblastic leukemia.
    Rytting M
    Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
    Lau KM; Saunders IM; Goodman A
    J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
    Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEGylated
    Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
    Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
    Bade NA; Lu C; Patzke CL; Baer MR; Duong VH; Law JY; Lee ST; Sausville EA; Zimrin AB; Duffy AP; Lawson J; Emadi A
    J Oncol Pharm Pract; 2020 Jan; 26(1):74-92. PubMed ID: 30917738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
    J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
    Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity study of pegaspargase.
    Ettinger LJ; Lerner ED; Manglani MV
    Indian Pediatr; 2000 Jun; 37(6):631-6. PubMed ID: 10869143
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia.
    Kaminski KS; Beach CL; Peden DB; Le U; Roehrs PA
    J Oncol Pharm Pract; 2016 Apr; 22(2):354-6. PubMed ID: 25567519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
    Daley RJ; Rajeeve S; Kabel CC; Pappacena JJ; Stump SE; Lavery JA; Tallman MS; Geyer MB; Park JH
    Leuk Lymphoma; 2021 Jan; 62(1):176-184. PubMed ID: 32985296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegaspargase-induced pancreatitis.
    Alvarez OA; Zimmerman G
    Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
    Liu L; Xie XT
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegaspargase: an alternative?
    Holle LM
    Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
    Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
    J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.